AcuCort Expands Trademark Protection to Canada
AcuCort strengthens its global presence with trademark protection for Zeqmelit® in Canada, marking a significant step in its international expansion.
Sammanfattning
AcuCort secures trademark protection for Zeqmelit® in Canada, enhancing its global brand strategy and supporting its ongoing commercialization efforts.
AcuCort AB, a promising player in the pharmaceutical industry, has announced a significant milestone in its strategic journey towards global expansion. The company has successfully secured trademark protection for its innovative product, Zeqmelit®, in Canada. This development is a testament to AcuCort's commitment to establishing a strong international presence and underscores the strategic importance of trademark protection in the company's ongoing commercialization phase.
Jonas Jönmark, CEO of AcuCort, expressed his enthusiasm about this achievement, stating, 'The fact that Zeqmelit® is now also protected as a trademark in Canada is an important step in our international expansion. It strengthens our ability to establish the product in new markets and is part of our strategic work to build a strong and protected global brand.'
Zeqmelit®, a rapidly dissolving oral film based on dexamethasone, is designed to treat severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and COVID-19 patients requiring supplemental oxygen therapy. The product is already approved in Sweden, Denmark, Norway, and Finland, and with this new trademark registration, AcuCort is poised to further its reach across the globe.
The trademark registration in Canada is valid in accordance with the dates of the International Registration and will be renewed in conjunction with the renewal of the International Registration on January 9, 2033. This adds to the existing trademark protections in all member states of the European Union, as well as in Norway, the United Kingdom, Switzerland, Australia, India, Israel, China, Japan, and the United States.
From an investment perspective, AcuCort's strategic moves to secure international trademark protection are promising. This not only strengthens the company's brand but also enhances its marketability across different regions, potentially leading to increased sales and revenue. Given the company's innovative product offering and strategic expansion efforts, investors might consider holding onto their shares as AcuCort continues to build its global brand.
Källa
Sammanfattning
AcuCort's CEO, Jonas Jönmark, emphasizes the strategic importance of trademark protection during the company's commercialisation phase. Zeqmelit® has now gained trademark protection in Canada, which is seen as a crucial step in AcuCort's international expansion efforts. The trademark registration is valid until January 2033 and can be renewed. Zeqmelit® is already trademarked in the EU, Norway, the UK, Switzerland, Australia, India, Israel, China, Japan, the US, and now Canada. AcuCort is commercializing Zeqmelit®, an oral film for treating severe allergic reactions, croup, chemotherapy-induced nausea, and COVID-19 patients needing oxygen. The product is approved in several Nordic countries, and AcuCort is listed on the Spotlight Stock Market.
